Pancreatic Cancer Research

Clinical trialPhase 1Unknown

Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients

Outcome
Outcome unknown
Phase
Phase 1
Status
Unknown
Study type
Interventional
Start
June 2022
Listed end
1 May 2025
Enrollment
230 participants
Sites
5
Primary outcomes
The adverse events (AEs); Determine the recommended Phase II dose (RP2D)
Sponsor type
Industry
Results posted
No
Last update
21 June 2022

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BPI-442096, a SHP2 inhibitor, in patients with advanced solid tumors.

Detailed description public domain (ClinicalTrials.gov)

The first-in-human (FIH) study of BPI-442096 will be an open-label, non-randomized, Phase 1 study utilizing a modified "3+3" dose escalation followed by an expansion phase in patients with KRAS G12 mutation, class-3 BRAF mutation, NF1 LOF mutation or RTK mutation, amplification or rearrangement advanced solid tumors. The primary objective is to determine safety and tolerability of BPI-442096, the MTD and RP2D. The secondary objectives are to assess the pharmacokinetic (PK) and pharmacodynamic (PD) profile, preliminary anti-tumor activity of BPI-442096.